<DOC>
	<DOCNO>NCT02519413</DOCNO>
	<brief_summary>The primary objective study retrospectively investigate change lymphocyte count lymphocyte subtypes , focus CD4+ CD8+ T cell , participant Tecfidera therapy least 6 month . The secondary objective investigate change lymphocyte subtypes CD4+ CD8+ T cell .</brief_summary>
	<brief_title>Tecfidera Lymphocyte Chart Review</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Dimethyl Fumarate</mesh_term>
	<criteria>Key Initiated Tecfidera treatment first time 27 March 2013 receive least 6 month continuous treatment Tecfidera Clinical diagnosis relapse form MS A baseline measurement ALC absolute CD4+ CD8+ count within 6 month prior Tecfidera initiation At least 1 measurement ALC absolute CD4+ CD8+ count Tecfidera therapy least 6 month Key Clinical diagnosis human immunodeficiency virus ( HIV ) acquire immunodeficiency syndrome ( AIDS ) prior Tecfidera initiation Participation DEFINE 109MS301 ( NCT00420212 ) CONFIRM 109MS302 ( NCT00451451 ) NOTE : Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>lymphocyte</keyword>
	<keyword>serious infection</keyword>
	<keyword>opportunistic infection</keyword>
	<keyword>Relapsing Forms</keyword>
</DOC>